Cover Image
市場調查報告書

第二型神經纖維瘤 (NF2):開發中產品分析

Neurofibromatoses Type II - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 277753
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
第二型神經纖維瘤 (NF2):開發中產品分析 Neurofibromatoses Type II - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 53 Pages
簡介

所謂第二型神經纖維瘤(NF2)是以神經系統非癌性腫瘤之增殖為特徵的一種疾病。沿著內耳到腦(聽覺神經)的情報運輸神經發症。其他神經產生的腫瘤最常以這種狀態發現。主要的症狀有聽障、耳鳴、平衡感異常等。

本報告提供第二型神經纖維瘤 (NF2) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

第二型神經纖維瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

第二型神經纖維瘤:企業開發中的治療藥

第二型神經纖維瘤:大學/機關研究中的治療藥

第二型神經纖維瘤:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

第二型神經纖維瘤:企業開發中的產品

第二型神經纖維瘤:大學/機關研究中的產品

第二型神經纖維瘤的治療藥的開發企業

  • Arno Therapeutics, Inc.
  • CalAsia Pharmaceuticals, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Novartis AG

第二型神經纖維瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

第二型神經纖維瘤:最近的開發平台趨勢

第二型神經纖維瘤:暫停中的計劃

第二型神經纖維瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8603IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type II - Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses Type II (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type II - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type II (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively for Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively for Neurofibromatoses Type II.

Neurofibromatoses Type II (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses Type II (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses Type II (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type II (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type II (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neurofibromatoses Type II Overview
  • Therapeutics Development
    • Pipeline Products for Neurofibromatoses Type II - Overview
    • Pipeline Products for Neurofibromatoses Type II - Comparative Analysis
  • Neurofibromatoses Type II - Therapeutics under Development by Companies
  • Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes
  • Neurofibromatoses Type II - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Neurofibromatoses Type II - Products under Development by Companies
  • Neurofibromatoses Type II - Products under Investigation by Universities/Institutes
  • Neurofibromatoses Type II - Companies Involved in Therapeutics Development
    • Arno Therapeutics, Inc.
    • Betta Pharmaceuticals Co. Ltd.
    • Lixte Biotechnology Holdings, Inc.
    • Novartis AG
    • Plex Pharmaceuticals, Inc.
  • Neurofibromatoses Type II - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-42 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FRAX-597 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • icotinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neurofibromatoses Type II - Dormant Projects
  • Neurofibromatoses Type II - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neurofibromatoses Type II, H2 2016
  • Number of Products under Development for Neurofibromatoses Type II - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Neurofibromatoses Type II - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Neurofibromatoses Type II - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
  • Neurofibromatoses Type II - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
  • Neurofibromatoses Type II - Pipeline by Novartis AG, H2 2016
  • Neurofibromatoses Type II - Pipeline by Plex Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Neurofibromatoses Type II - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Neurofibromatoses Type II, H2 2016
  • Number of Products under Development for Neurofibromatoses Type II - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top